Log In
BCIQ
Print this Print this
 

Hextend

Also known as: hetastarch

  Manage Alerts
Collapse Summary General Information
Company BioTime Inc.
Description6% hetastarch in lactated electrolyte injection
Molecular Target Not available
Mechanism of ActionNA
Therapeutic ModalityMacromolecule: Polysaccharide
Latest Stage of DevelopmentMarketed
Standard IndicationHypovolemia
Indication DetailsTreat hypovolemia
Regulatory Designation
PartnerPfizer Inc.;
Summit Pharmaceuticals International Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,700.0M

$1,700.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/03/2015

$1,700.0M

$1,700.0M

0

Get a free BioCentury trial today